Immutep (IMMP) AI Stock Analysis

• Market Cap: $219.24M
• Dividend Yield: N/A
• Average Volume (3M): 77.67K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.41
• Revenue Growth: N/A
• EPS Growth: 15.17%
• Country: US
• Employees: 41
• Sector: Healthcare
• Sector Strength: 66
• Industry: Biotechnology
• EPS (TTM): -0.22
• Shares Outstanding: 146,038,960
• 10 Day Avg. Volume: 90,853
• 30 Day Avg. Volume: 77,672
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): N/A
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $12.00
• Price Target Upside: 694.70% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

Immutep's overall stock score reflects substantial financial and technical challenges common in biotech firms. The company shows a stable balance sheet and significant financing capability, crucial for its high R&D expenses. However, persistent losses, negative cash flow, and bearish technical indicators weigh heavily on the score. Valuation is constrained by negative earnings, highlighting the risk associated with investing in a development-stage biotech firm.

Positive Factors

Clinical Trials

The combination of efti and Keytruda has demonstrated a promising 67% 12-month overall survival rate, significantly higher than historical results for Keytruda monotherapy.

Market Opportunity

The TACTI-004 trial targets a broad NSCLC setting, potentially opening a large market opportunity for Immutep's efti.

Negative Factors

Safety Concerns

The first-in-human P1 trial for IMP761 is progressing cautiously, with safety being a critical factor for advancement.

Trial Challenges

The success of the TACTI-004 trial is critical for Immutep, as it is pivotal for opening large market opportunities.

Immutep Business Overview & Revenue Model

Company Description

Immutep (IMMP) is a biotechnology company focused on developing novel immunotherapy treatments for cancer and autoimmune diseases. The company operates primarily in the healthcare and biotechnology sectors, with a core focus on leveraging its proprietary technology to modulate the immune system. Immutep's lead product candidate, eftilagimod alpha (IMP321), is a soluble LAG-3 protein designed to enhance the immune response in cancer patients. In addition to eftilagimod alpha, Immutep is advancing other therapeutic candidates in its pipeline, including IMP761 for autoimmune diseases and partnerships involving LAG-3 products.

How the Company Makes Money

Immutep primarily generates revenue through a combination of licensing agreements, collaborative research, and development partnerships. The company partners with other pharmaceutical and biotechnology companies to co-develop and commercialize its therapeutic candidates. Revenue streams include upfront payments, milestone payments, and royalties from these partnerships. Immutep's collaborations with major industry players, such as Merck and GlaxoSmithKline, play a crucial role in its revenue generation strategy by providing funding and expertise to advance its product pipeline. Additionally, Immutep may receive government grants and financial support to aid in the development of its immunotherapy treatments.

Immutep Financial Statement Overview

Summary

Immutep's financial performance reflects challenges typical for development-phase biotech firms. The income statement shows ongoing losses with negative margins, while the balance sheet is stable due to strong equity and low leverage. Cash flow issues persist due to high R&D costs, but are partially mitigated by effective financing strategies.

Income Statement

Immutep displays a challenging income statement with a negative gross profit margin and consistently negative net income. Revenue growth has been volatile, with recent growth from a low base. The EBIT and EBITDA margins are deeply negative, reflecting ongoing operational and structural challenges. The company’s financial trajectory indicates difficulty in achieving profitability in the near term, common in biotechs during extensive R&D phases.

Balance Sheet

The balance sheet shows a strong equity position with low debt levels, resulting in a favorable debt-to-equity ratio. The equity ratio is robust, highlighting financial stability and a solid asset base. However, the continuous losses and cash burn could pressure equity if not offset by ongoing financing activities, a typical scenario in the biotechnology sector.

Cash Flow

Cash flow analysis reveals negative operating and free cash flows as expected in an R&D-intensive biotech firm. Operating cash flow to net income ratio is not favorable, indicating significant cash burn relative to revenue generation. Free cash flow remains negative, but the company has managed significant financing to support operations, a critical factor for sustaining R&D activities.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
4.88M	3.84M	3.51M	170.37K	3.97M	7.49M
	Gross Profit
-41.56M	-37.70M	1.44M	-1.89M	1.90M	-14.99M
	EBIT
-96.29M	-88.10M	-44.94M	-33.94M	-19.56M	-16.02M
	EBITDA
-48.74M	-44.54M	-39.57M	-31.87M	-17.77M	-13.46M
	Net Income Common Stockholders
-43.87M	-42.72M	-39.90M	-32.21M	-29.90M	-13.47M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
28.07M	181.88M	123.42M	80.00M	60.13M	26.32M
	Total Assets
32.34M	201.58M	147.45M	102.17M	82.03M	46.60M
	Total Debt
0.00	1.59M	1.23M	1.73M	2.82M	9.05M
	Net Debt
-11.02M	-160.20M	-122.19M	-78.26M	-57.31M	-17.27M
	Total Liabilities
2.98M	12.06M	10.98M	8.09M	8.76M	13.30M
	Stockholders Equity
29.36M	189.52M	136.47M	94.08M	73.27M	33.30M
Cash Flow		Free Cash Flow
-46.43M	-35.75M	-35.93M	-30.25M	-17.66M	-10.86M
	Operating Cash Flow
-45.96M	-34.82M	-35.88M	-30.23M	-17.64M	-10.84M
	Investing Cash Flow
-73.32M	-21.02M	-31.00K	-22.91K	-15.60K	-19.35K
	Financing Cash Flow
95.24M	95.18M	76.04M	50.33M	52.68M	20.48M

Immutep Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.51
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMMP, the sentiment is Negative. The current price of 1.51 is below the 20-day moving average (MA) of 1.63, below the 50-day MA of 1.78, and below the 200-day MA of 2.01, indicating a bearish trend. The MACD of -0.10 indicates Positive momentum. The RSI at 42.50 is Neutral, neither overbought nor oversold. The STOCH value of 43.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IMMP.

Immutep Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CMPX	60 Neutral	$241.99M	―	-36.07%	―	―	-7.93%
ITOS	51 Neutral	$248.65M	―	-23.06%	―	177.89%	-10.95%
Sector *	51 Neutral	$5.19B	3.13	-40.94%	2.95%	17.94%	2.00%
IMMP	48 Neutral	$219.24M	―	-31.16%	―	―	15.17%
AVIR	47 Neutral	$254.01M	―	-33.88%	―	―	-22.66%
YMAB	44 Neutral	$212.07M	―	-30.74%	―	3.38%	-36.40%
ATXS	39 Underperform	$227.99M	―	-33.52%	―	―	27.92%